Peter Whelan | Academic Influence

Peter Whelan 's AcademicInfluence.com Rankings

Peter Whelan

Law

#2065

World Rank

#2572

Historical Rank

Corporate Law

#15

World Rank

#15

Historical Rank

International Law

#1373

World Rank

#1642

Historical Rank

Download Badge

Law

Peter Whelan 's Degrees

Doctorate Law University of Law

Why Is Peter Whelan Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter Whelan is a professor of law at the School of Law, University of Leeds. A qualified New York Attorney-at-Law, Whelan conducts research in competition law and criminal law. He published the first full-length monograph on the criminal enforcement of competition law with Oxford University Press.

(See a Problem?)

Peter Whelan 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial (1999) (349)
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. (2006) (344)
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. (1996) (320)
Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. (1993) (257)
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. (2009) (256)
Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer (2005) (197)
Maximal Androgen Blockade: Final Analysis of EORTC Phase III Trial 30853 (1998) (166)
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). (2008) (148)
Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. (2008) (140)
Atlas of Diseases of the Kidney (2001) (112)
Prostate-specific membrane antigen. (1998) (87)
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol (2021) (87)
The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. (1996) (83)
Prostate-specific membrane antigen: evidence for the existence of a second related human gene. (1995) (81)
Prostate cancer treated by anti-androgens: is sexual function preserved? (2000) (81)
Soluble forms of the adhesion molecule E-cadherin in urine. (1995) (72)
Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma (2003) (69)
Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. (2014) (69)
Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the South European Uroncological Group. (2014) (67)
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. (2004) (62)
Zinc, vitamin A and prostatic cancer. (1983) (60)
Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. (2011) (58)
An evaluation of the immunochemical measurement of prostatic acid phosphatase and prostatic specific antigen in carcinoma of the prostate. (1986) (56)
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. (2003) (55)
A pilot study of intermittent androgen deprivation in advanced prostate cancer. (1998) (51)
Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers (2005) (49)
A Principled Argument for Personal Criminal Sanctions as Punishment Under EC Cartel Law (2007) (43)
Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. (1988) (42)
Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer (1999) (39)
The Criminalization of European Cartel Enforcement: Theoretical, Legal, and Practical Challenges (2014) (38)
The role of the public private partnership in Food Fraud prevention — includes implementing the strategy (2016) (34)
Bone alkaline phosphatase and prostate‐specific antigen in the monitoring of prostate cancer (1994) (31)
The Use of Real-Time Reverse Transcription-PCR for Prostate-Specific Antigen mRNA to Discriminate between Blood Samples from Healthy Volunteers and from Patients with Metastatic Prostate Cancer (2004) (31)
Immunological responsiveness after transurethral resection of the prostate: general versus spinal anaesthetic. (1982) (30)
Cartel Criminalization and the Challenge of ‘Moral Wrongfulness’ (2013) (29)
Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer. (1998) (26)
Phase III intermittent MAB vs continuous MAB. (2006) (26)
Tumor markers in prostate cancer (1992) (26)
Interactions of retinoic acid and androgens in human prostatic tissue (1990) (25)
Survival from bladder cancer in England and Wales up to 2001 (2008) (25)
DIRECTORATE FOR FINANCIAL AND ENTERPRISE AFFAIRS COMPETITION COMMITTEE (2019) (25)
Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. (1999) (24)
Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853) (1993) (22)
An Evaluation of the Immunochemical Measurement of Prostatic Acid Phosphatase and Prostatic Specific Antigen in Carcinoma of the Prostate (1988) (21)
Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer (2003) (21)
Preliminary results of a MRC randomised controlled trial of post-operative irrigation of superficial bladder cancer (2001) (21)
The Medical Treatment of Metastatic Renal Cell Cancer (2003) (19)
Retinoids in Chemoprevention (1999) (17)
Early catheter removal following transurethral prostatectomy--impact on length of hospital stay. (1994) (17)
Evaluation of quality of life, side effects and duration of therapy in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation (2008) (17)
Intravesical mitomycin C for the treatment of recurrent superficial bladder tumours. (1987) (15)
LONG-TERM EFFICACY RESULTS OF EORTC GU GROUP STUDY 30911 COMPARING EPIRUBICIN, BACILLUS CALMETTEGUERIN (BCG), AND BCG PLUS ISONIAZID IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE TA T1 PAPILLARY CARCINOMA OF THE BLADDER (2008) (15)
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the “European organization for research and treatment of cancer” (EORTC) protocol 30892 (2003) (14)
Prostate cancer : diagnosis and clinical management (2014) (12)
The Treatment of Non–Muscle-Invasive Bladder Cancer with Intravesical Chemotherapy and Immunotherapy☆ (2007) (11)
Unusual squamous cell carcinoma of the scrotum arising from a well healed, innocuous scar of an infertility procedure: a case report. (2007) (10)
Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma. (2003) (10)
A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour. (1990) (10)
Triptorelin embonate: a 6-month formulation for prostate cancer (2010) (10)
Criminal sanctions: An overview of EU and national case law (2014) (10)
PHASE III STUDY OF INTERMITTENT MAB VERSUS CONTINUOUS MAB - AN INTERNATIONAL COOPERATIVE STUDY - QUALITY OF LIFE (2006) (10)
Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups. (1991) (9)
The motion: Radical cystectomy in the elderly is becoming a standard treatment for bladder cancer. (2007) (9)
Are we promoting stress and anxiety? (1997) (9)
Cytosolic retinoic acid‐binding protein in human prostatic dysplasia and neoplasia (1987) (9)
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array (2016) (9)
Intravesical mitozantrone in recurrent superficial bladder cancer: a phase II study. (1995) (8)
An argument in favour of the passing-on defence: A response to private actions in competition law (2012) (7)
The Contribution of Bilateral Trade or Competition Agreements to Competition Law Enforcement Cooperation between Canada and Costa Rica (2005) (7)
Legal Certainty and Cartel Criminalisation within the EU Member States (2012) (7)
'Consumer Detriment' and its Application in EC and UK Competition Law (2006) (7)
Bladder cancer--contemporary dilemmas in its management. (2008) (7)
EBU Announces the Curriculum for Urologic Training in Europe (2011) (7)
The Contribution of Bilateral Trade or Competition Agreements to Competition Law Enforcement Cooperation between Canada and Chile (2005) (7)
PSA DOUBLING TIME AS PREDICTOR OF OBJECTIVE PROGRESSION AND DEATH IN PATIENTS WITH T0-4 N0-2 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL DEFINITIVE TREATMENT ON WATCHFUL WAITING (EORTC 30891) (2006) (7)
303Patients with asymptomatic prostate cancer T.0-4 N.0-2 M.0 not suitable for local definitive treatment: Do they need immediate androgen deprivation? (2005) (7)
Cytosolic retinoic acid-binding protein in human prostatic dysplasia and neoplasia. (1988) (6)
19 WHICH SUBGROUPS OF PATIENTS WITH NEWLY DIAGNOSED TO-4 NO-2 MO PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT (EORTC 30891) ARE AT RISK TO DIE FROM PROSTATE CANCER AND BENEFIT FROM IMMEDIATE ANDROGEN DEPRIVATION? (2007) (6)
Are we entering the era of truly minimally invasive destructive techniques for the treatment of urologic tumours and will these therapies stay in urologists' hands? (2007) (5)
Choosing the right intravesical chemotherapeutic agent. Results of an in vitro monolayer cell culture assay. (1984) (5)
Trading Negotiations Between Retailers and Suppliers: A Fertile Ground for Anti-Competitive Horizontal Information Exchange? (2009) (5)
Does failure of single hormone therapy delineate hormone refractoriness for prostate cancer? (2008) (5)
Book Review: Criminalization of Competition Law Enforcement: Economic and Legal Implications for the EU Member States (Cseres, Schinkel and Vogelaar (eds)) (2006) (5)
Contemplating the Future: Personal Criminal Sanctions for Infringements of EC Competition Law (2008) (5)
[Link between rheumatoid arthritis and cancer]. (2006) (5)
804 IMMEDIATE OR DEFERRED ANDROGEN DEPRIVATION FOR PATIENTS WITH PROSTATE CANCER AND NO LOCAL TREATMENT OF THE PROSTATE: LONG TERM RESULTS OF EORTC 30891 (2011) (5)
Planning primary therapy. (2000) (5)
Dipstick Haematuria: Its Association with Smoking and Nonsteroidal Anti-Inflammatory Drugs (1990) (5)
New developments in the etiopathogenesis and treatment of HIV-related Kaposi's sarcoma. (2000) (5)
IS THE DEGREE OF PSA DECLINE AFTER IMMEDIATE ANDROGEN DEPRIVATION A PROGNOSTIC FACTOR FOR OUTCOME IN PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT? (RESULTS FROM THE EORTC 30891 TRIAL) (2006) (5)
Consumer Interest in Competition Law Cases (2006) (4)
1659: Immediate Versus Deferred Androgen Deprivation in Patients with Asymptomatic Prostate Cancer T0-4 N0-2 M0 Not Suitable for Local Definitive Treatment (2005) (4)
Resisting the Long Arm of Criminal Antitrust Laws: Norris V the United States (2009) (4)
WHICH PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT DO NOT NEED IMMEDIATE TREATMENT IN EORTC TRIAL 30891? (2006) (4)
Improving Criminal Cartel Enforcement in the UK: The Case for the Adoption of Bis's “Option 4” (2012) (4)
The case against radical prostatectomy. (2005) (4)
Use of intravenous fosfestrol tetrasodium (Honvan) infusion in treatment of symptomatic advanced prostate cancer (1998) (4)
Competition Law and Criminal Justice (2018) (3)
Drug treatment in urology (2006) (3)
Retinoic acid and prostatic cancer cell growth. (1990) (3)
354 LONG TERM RESULTS OF IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRI-VATION IN PATIENTS WITH NO LOCAL TREATMENT FOR T0–4 N0–2 M0 PROSTATE CANCER (EORTC 30891) (2011) (3)
A comparative trial of aztreonam versus gentamicin in the treatment of urinary tract infections (2006) (3)
Treatment of Superficial Bladder Cancer: A Discussion on Intravesical Immunotherapy and Intravesical Chemotherapy (2004) (3)
CORTISOL AND POSTOPERATIVE BLOOD CELL COUNTS (1980) (3)
142 PHASE III STUDY OF INTERMITTENT MONOTHERAPY VERSUS CONTINUOUS COMBINED ANDROGEN DEPRIVATION (2007) (3)
716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOS MAB (2011) (3)
An Analysis Of Hedge Fund Styles using the Gap Statistic (2005) (3)
Evaluation of quality-of-life side effects and duration of therapy in a phase III study of intermittent monotherapy versus continuous combined androgen deprivation (2008) (3)
The 'Consumer Welfare' Standard as a Form of Substantive Protection for Consumers under European Competition Law (2009) (2)
When Markets are Failing: Part II (2007) (2)
Terminal care of patients with prostatic carcinoma. (1988) (2)
Selective Distribution in the Age of Online Retail (2010) (2)
382: Which Subgroups of Patients are at risk to die from Prostate Cancer and Benefit from Immediate Androgen Deprivation if they are not Suitable for local Treatment with Curative intent of Newly Diagnosed Prostate Cancer T0-4 N0-2 MO (EORTC 30891)? (2007) (2)
Re-examining Trans-Atlantic Similarities and Divergences in Substantive and Procedural Competition Law (2009) (2)
Five years survival and risk of death in a phase III study of intermmittent monotherapy versus continuous combined androgen deprivation (2008) (2)
The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma (2009) (2)
Non-Surgical Ablative Treatments for Small Renal Tumours Less Than 4 cm (2006) (2)
Multidisciplinary Symposium — Prostate Cancer (2015) (2)
The Hunting Metaphor in The Fox and Other Works (1989) (2)
The Long Perspective: Prostate Cancer as a Chronic Disease (2014) (2)
Section 47 of the Enterprise and Regulatory Reform Act 2013: A Flawed Reform of the UK Cartel Offence (2015) (1)
1138: Phase III Study of Intermittent Mab Versus Continous Mab International Cooperative Study (2005) (1)
800 PHASE II STUDY OF INTERMITTENT MAB VS. CONTINUOUS MAB (2011) (1)
Prostatitis and Urethritis (1999) (1)
801 TIME TO PROGRESSION SHOULD NOT BE USED TO INFER THE ULTIMATE BENEFIT OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER (2011) (1)
Editorial comment on: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. (2008) (1)
563 Effects of prior use of statins in a phase 3 study of intermittent monotherapy versus continuous combined androgen deprivation (2015) (1)
972 Effects of prior use of statins in a phase 3 study of intermittent versus continuous combined androgen deprivation (2014) (1)
665: Baseline PSA and PSA Doubling Time Predict the Risk of Objective Progression and Death in Patients with T0-4 N0-2 M0 Prostate Cancer on Watchful Waiting (2006) (1)
Hormone Therapy in Prostate Cancer: Moving into the 21st Century (2005) (1)
803 PHASE III STUDY OF INTERMITTENT MONOTHERAPY VS CONTINUOUS COMBINED ANDROGEN DEPRIVATION (2011) (1)
PD27-10 EFFECTS OF PRIOR USE OF STATINS IN A PHASE 3 STUDY OF INTERMITTENT VERSUS CONTINUOUS COMBINED ANDROGEN DEPRIVATION (2014) (1)
Contemporary results of radical radiotherapy for bladder transitional cell carcinoma in a district general hospital. (1999) (1)
Protecting Human Rights in the Context of European Antitrust Criminalisation (2010) (1)
The Accrington Pals (2018) (1)
Private Enforcement and Commission Decisions: The Crehan Case (2007) (1)
The Role of Third Parties in the Competition Enforcement Landscape: A Critical Review (2007) (1)
CISAC: How Difficult it is to Prove a Concerted Practice (2013) (1)
Strengthening Competition Law Enforcement in Ireland: The Competition (Amendment) Act 2012 (2013) (1)
European Cartel Criminalization and Regulation 1/2003: Avoiding Potential Problems (2017) (1)
D. H. Lawrence: Myth and metaphysic in The rainbow and Women in love (1988) (1)
Antitrust law and policy in a global market insight (2007) (1)
Criminal Cartel Enforcement in the European Union: Avoiding a Human Rights Trade-Off (2011) (1)
664: PSA Decline from Baseline is not a Prognostic Factor for Outcome in Hormonally Treated Patients with T0-4N0M0 Prostate Cancer not Suitable for Local Treatment with Curative Intent Treated in Eortc 30891 (2006) (0)
The immunological effects of anaesthesia and surgery (1986) (0)
The Consistent Application of EU Competition Law (2017) (0)
Austin Journal of Cancer and Clinical Research What are we Aiming to Achieve in Our Patients with Advanced Prostate Cancer (2017) (0)
Re: Docetaxel and Estramustine Compared With Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer (2006) (0)
Book Review: Efficiency and Justice in European Antitrust Enforcement (Wils) (2009) (0)
European Antitrust Criminalization and the Challenge of Deterrence Theory (2014) (0)
Antitrust Criminalization as a Legitimate Deterrent (2021) (0)
CONTEMPORARY RESULTS OF RADICAL RADIOTHERAPY FOR BLADDER TRANSITIONAL CELLCARCINOMA IN A DISTRICT GENERAL HOSPITAL WITH CANCER-CENTRE STATUS (1999) (0)
Metastic Renal Cancer and the Role of Surgery (2008) (0)
An Analysis of Methodology in Clinical Studies of Prostate Cancer: Misled and Misinterpreted (2003) (0)
Book review: Presumption of Innocence in EU Anti-Cartel Enforcement, by Aiste? Mickonyte. (Leiden: Brill / Nijhoff, 2019) (2020) (0)
Global Competition Law and Economics . By Einer Elhauge and Damien Geradin. [Oxford: Hart Publishing, 2007. xii, 1170, and (Index) 58 pp. Paperback £35.00. ISBN 978-1-84113-465-9.] (2008) (0)
Criminalization of Competition Law Enforcement: Economic and Legal Implications for the Eu Member States. KJ Cseres, M-P Schinkel and FOW Vogelaar (eds). (2006) (0)
Fundamentals of Clinical Psychopharmacology (2015) (0)
893 PHASE III STUDY OF INTERMITTENT MONOTHERAPY VS CONTINUOS COMBINED ANDROGEN DEPRIVATION (2011) (0)
European Antitrust Criminalization and the Second Challenge of Design (2014) (0)
Quantitative analysis of cellular retinoic acid-binding protein in the human prostate (1986) (0)
Radical prostatectomy versus watchful waiting (2006) (0)
Morality and Its Restraining Influence on European Antitrust Criminalisation (2009) (0)
Lawrence's Language of Heaven and Earth (2010) (0)
The Earthly Paradise (2004) (0)
Choosing the Right Intravesical Chemotherapeutic Agent. Results of an In Vitro Monolayer Cell Culture Asay (1985) (0)
Foreward to Special Edition: Criminal Sanctions - An Overview of EU and National Case Law (2012) (0)
Cartel criminalisation and due process: the challenge of imposing criminal sanctions alongside administrative sanctions within the EU (2020) (0)
For you, commissar, the war is over (2012) (0)
APOLLO AND LADY CHATTERLEY (1984) (0)
The expression profile of cytokines and cytokine receptors in normal kidney and renal cell carcinoma tissue and cell lines (2003) (0)
Book Review: What About Law? (Barnard, O'Sullivan and Virgo (eds)) (2008) (0)
Prostate-specific membrane antigen genes lie within duplicated regions on human chromosome 11P11.2 and 11q14loci (1997) (0)
Manage urinary tract infections. (2006) (0)
European Antitrust Criminalization and the Challenge of Retribution Theory (2014) (0)
EVALUATION OF QUALITY OF LIFE, SIDE EFFECTS AND DURATION OF THERAPY IN A PHASE 3 STUDY OF INTERMMITTENT MONOTHERAPY VERSUS CONTINOUS COMBINED ANDROGEN DEPRIVATION (2008) (0)
Sanctions in EU competition law: principles and practice (2015) (0)
The Herbal Bed (1996) (0)
Drugs in Superficial Bladder Cancer (2008) (0)
The Degussa Case (2008) (0)
Two on Lawrence (2010) (0)
Case report: therapeutic embolization to control haematuria from transitional cell carcinoma of the kidney. (1991) (0)
The Criminal Law of Competition in the UK and in the US: Failure and Success Mark Furse. (2013) (0)
352 TIME TO DISEASE PROGRESSION IS NOT AN APPROPRIATE ENDPOINT IN STUDIES OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER (2011) (0)
Book Review: Butterworths Competition Law Handbook (Lindrup (ed)) (2008) (0)
Critical historical enquiry for a socially just and sustainable world (2021) (0)
Potential Theoretical Justifications for European Antitrust Criminalization (2014) (0)
Scots in Glasgow: Scottish Chamber Orchestra Winds: RCS Stevenson Winds (2016) (0)
The UK Government issues a consultation on options for reforming the private enforcement of competition law (2012) (0)
Comparison of treatment outcome for radical surgery versus radical radiotherapy for invasive bladder cancer treated in a UK specialist treatment centre (2007) (0)
Something of a Burden: Is the Passing-On Defence Appropriate? (2008) (0)
The Emerging Contribution of Director Disqualification in UK Competition Law (2020) (0)
1592: Patients with T0-4N0M0 Prostate Cancer Not Suitable for Local Treatment with Curative Intent (EORTC 30891): Which Subgroup Needs or does Not Need Immediate Treatment? (2006) (0)
Concluding Remarks on the Theoretical, Legal, and Practical Challenges of European Antitrust Criminalization (2014) (0)
European Antitrust Criminalization and the Third Challenge of Design (2014) (0)
An Introduction to European Antitrust Criminalization and Its Theoretical, Legal, and Practical Challenges (2014) (0)
Re: The Dissemination of Cancer by Transurethral Resection of Locally Advanced Prostate Cancer, by G. E. Hanks, S. Leibel and S. Kramer, J. Urol., 129: 309-311, 1983 (1984) (0)
560 ADJUVANT NODAL RADIOTHERAPY IN SQUAMOUS CELL CARCINOMA OF THE PENIS (2010) (0)
The Antitrust Religion. Edwin S Rockefeller. (2008) (0)
Re-Examining Trans-Atlantic Divergences in Substantive and Procedural Competition Law (2009) (0)
Intervention and the Internal Market: Contemporary European Competition Initiatives Concerning Distribution in the Market for New Cars (2008) (0)
Book Review: The Antitrust Religion (Rockefeller) (2008) (0)
Current Competition Law: Volume V (2007) (0)
Controversial topics in surgery. The case against radical prostatectomy. (2005) (0)
Time to reflect: helping patients to understand the natural history of prostate cancer (2016) (0)
BBC Radio 3: Poulenc 50 Years On with Michael Collins (2014) (0)
A Principled Argument for Personal Criminal Sanctions for Infringements of EC Competition Law (2007) (0)
Pine creek surface water investigation. Volumes 1 & 2 (1982) (0)
Drugs used for personality disorders and behavioural disturbance (2015) (0)
Personal View (1980) (0)
Horse race gambling markets : an empirical test of efficiency / by Peter Whelan. (1985) (0)
European Antitrust Criminalization and the Challenge of Legal Certainty (2014) (0)
LONG-TERM EFFICACY RESULTS OF EORTC GU GROUP STUDY 30911 COMPARING EPIRUBICIN, BACILLUS CALMETTE- GUERIN (BCG), AND BCG PLUS ISONIAZID IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 BLADDER CARCINOMA (2008) (0)
Editorial comment on: laparoscopic partial nephrectomy for hilar tumours: technique and results. (2008) (0)
Beyond the Theoretical: Articulating Enforcement Strategies for Successful European Antitrust Criminalization (2016) (0)
In Reply to Dr. Rosario et al. (2008) (0)
Editorial comment on: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. (2008) (0)
Endocrine events in prostate cancer: a paradigm shift in our understanding? (2008) (0)
Subject Index Vol. 35, 1999 (1999) (0)
Vol. 35, 1999 (1999) (0)
Applying Ne Bis in Idem to Commission Proceedings Implicating Article 11(6) of Regulation 1/2003: Case C-857/19 Slovak Telekom (2021) (0)
Dysfunctional organisations : a role for the corporate psychotherapist (2008) (0)
Past Imperfects and Present Indicatives (1986) (0)
European Antitrust Criminalization and the Second Challenge of Due Process (2014) (0)
Hedge fund style analysis with the gap statistic (2010) (0)
A Tale of Two Cities : Belfast/Beirut (1990) (0)
Beyond the Theoretical: Articulating the Enforcement Strategies for a Successful Policy of European Antitrust Criminalization (2017) (0)

This paper list is powered by the following services:

Other Resources About Peter Whelan

en.wikipedia.org

What Schools Are Affiliated With Peter Whelan ?

Peter Whelan is affiliated with the following schools:

Image Attributions

Image Source for Peter Whelan